Adalimumab

Generic Name: Adalimumab

Brand Names: Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma

Drug Type: Biotech

Chemical Formula: -

CAS Number: 331731-18-1

Unique Ingredient Identifier: FYS6T7F842

Background: Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...

Indication: Adalimumab is indicated for the following conditions:

Adalimumab has also been used off-label to treat Pyoderma gangrenosum.

Associated Conditions: Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum

Associated Therapies: -

Clinical Trials

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Phase 2

Completed

Conditions: Focal Segmental Glomerulosclerosis

Interventions: Drug: Lisinopril, losartan, and atorvastatin
Drug: Adalimumab
Drug: galactose

First Posted Date: 2008-12-24

Last Posted Date: 2016-07-11

Lead Sponsor: NYU Langone Health

Target Recruit Count: 32

Registration Number: NCT00814255

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸
Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States

and more 15 locations

Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)

Phase 4

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Adalimumab
Drug: Etanercept
Drug: Adalimumab placebo

First Posted Date: 2008-11-24

Last Posted Date: 2012-10-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 13

Registration Number: NCT00796705

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸
Feinstein Institute for Medical Research NS-LIJ, Manhassett, New York, United States

and more 13 locations

Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

Phase 3

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Adalimumab

First Posted Date: 2008-10-20

Last Posted Date: 2016-01-26

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 32

Registration Number: NCT00775437

Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's

Phase 3

Completed

Conditions: Crohn's Disease With Perianal Fistulas

Interventions: Drug: adalimumab
Drug: ciprofloxacin

First Posted Date: 2008-08-18

Last Posted Date: 2012-04-17

Lead Sponsor: Foundation for Liver Research

Target Recruit Count: 76

Registration Number: NCT00736983

Locations: 🇳🇱
LUMC, Leiden, Netherlands
🇳🇱
St Antonius ziekenhuis, Nieuwegein, Netherlands
🇳🇱
UMC Radboud, Nijmegen, Netherlands

and more 10 locations

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)

Withdrawn

Conditions: Rheumatoid Arthritis

Interventions: Drug: infliximab
Drug: etanercept
Drug: adalimumab

First Posted Date: 2008-07-29

Last Posted Date: 2015-06-01

Lead Sponsor: Merck Sharp & Dohme LLC

Registration Number: NCT00724672

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Phase 2

Withdrawn

Conditions: Pyoderma Gangrenosum

Interventions: Drug: adalimumab

First Posted Date: 2008-06-05

Last Posted Date: 2019-12-20

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT00690846

Locations: 🇺🇸
Wake Forest University Health Sciences Dermatology, Winston-Salem, North Carolina, United States

Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

Phase 2

Withdrawn

Conditions: Sarcoidosis

Interventions: Drug: adalimumab

First Posted Date: 2008-06-05

Last Posted Date: 2017-11-06

Lead Sponsor: Wake Forest University

Registration Number: NCT00690911

Locations: 🇺🇸
Wake Forest University Health Sciences Dermatology, Winston-Salem, North Carolina, United States

Adalimumab for Inflammatory Osteoarthritis

Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Drug: adalimumab

First Posted Date: 2008-05-29

Last Posted Date: 2012-06-14

Lead Sponsor: University of Alberta

Target Recruit Count: 20

Registration Number: NCT00686439

Locations: 🇨🇦
The University of Alberta Hospital, Edmonton, Alberta, Canada

Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Adalimumab
Drug: Placebo

First Posted Date: 2008-04-17

Last Posted Date: 2015-11-24

Lead Sponsor: University of Aarhus

Target Recruit Count: 180

Registration Number: NCT00660647

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: adalimumab

First Posted Date: 2008-03-31

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 420

Registration Number: NCT00647270

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy